SRR1313148
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.550
- MYC_TARGETS_V1+0.510
- MYC_TARGETS_V2+0.470
- G2M_CHECKPOINT+0.450
- SPERMATOGENESIS+0.270
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.240
- OXIDATIVE_PHOSPHORYLATION+0.230
- MITOTIC_SPINDLE+0.140
- DNA_REPAIR+0.090
- ALLOGRAFT_REJECTION+0.080
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.580
- ANGIOGENESIS-0.560
- INTERFERON_ALPHA_RESPONSE-0.470
- TGF_BETA_SIGNALING-0.450
- UV_RESPONSE_DN-0.430
- APICAL_JUNCTION-0.400
- COAGULATION-0.390
- MYOGENESIS-0.390
- TNFA_SIGNALING_VIA_NFKB-0.390
- INTERFERON_GAMMA_RESPONSE-0.370
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8518197 | — | E | 0.902 |
| 2 | SAMN03290897 | — | — | 0.898 |
| 3 | BS_TZVFR600 | medulloblastoma | — | 0.896 |
| 4 | TCGA-A1-A0SO-01A-22R-A084-07 | — | E | 0.893 |
| 5 | 20090275.TNBC | — | E | 0.890 |
| 6 | SRR15030859 | — | — | 0.890 |
| 7 | AUR-AG0N-TTM1-A-1-1-R-A743-41 | — | E | 0.889 |
| 8 | TCGA-CV-6948-01A-11R-1915-07 | — | — | 0.888 |
| 9 | SRR8518243 | — | E | 0.887 |
| 10 | 50f787fb-b508-4c55-ba88-9942852d36e3 | — | — | 0.885 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.550 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.510 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.470 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.450 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.270 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.240 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.230 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.140 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.090 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.080 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.050 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.040 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.020 | Inavolisib | — uncovered |